Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 698,689
  • Shares Outstanding, K 44,137
  • Annual Sales, $ 90,860 K
  • Annual Income, $ -8,140 K
  • 60-Month Beta 2.66
  • Price/Sales 7.51
  • Price/Cash Flow N/A
  • Price/Book 7.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.02
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate -0.04
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.40 +16.49%
on 10/08/19
16.24 -3.88%
on 09/23/19
-0.46 (-2.86%)
since 09/20/19
3-Month
13.40 +16.49%
on 10/08/19
19.78 -21.08%
on 08/01/19
-2.86 (-15.48%)
since 07/22/19
52-Week
10.51 +48.53%
on 10/29/18
21.00 -25.68%
on 02/26/19
+4.32 (+38.26%)
since 10/22/18

Most Recent Stories

More News
Vericel to Report Third-Quarter 2019 Financial Results on November 5, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter...

VCEL : 15.61 (-1.39%)
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness...

VCEL : 15.61 (-1.39%)
MDWD : 2.85 (+1.06%)
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

VCEL : 15.61 (-1.39%)
Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present...

VCEL : 15.61 (-1.39%)
Vericel to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

MS : 45.25 (-0.29%)
VCEL : 15.61 (-1.39%)
Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018

VCEL : 15.61 (-1.39%)
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

VCEL : 15.61 (-1.39%)
Vericel to Report Second-Quarter 2019 Financial Results on August 6, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter...

VCEL : 15.61 (-1.39%)
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 15.61 (-1.39%)
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

MACI Revenue Increased 38% Over First Quarter 2018

VCEL : 15.61 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade VCEL with:

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 16.46
1st Resistance Point 16.04
Last Price 15.61
1st Support Level 15.35
2nd Support Level 15.08

See More

52-Week High 21.00
Fibonacci 61.8% 17.00
Fibonacci 50% 15.76
Last Price 15.61
Fibonacci 38.2% 14.52
52-Week Low 10.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar